Vol 7, No 3 (2016)
Review paper
Published online: 2017-02-23
The role of idelalisib in the treatment of patients with chronic lymphocytic leukemia
Hematologia 2016;7(3):217-230.
Abstract
B-cell receptor (BCR) activation in chronic lymphocytic leukemia (CLL) cells leads to stimulation of signaling pathways warranting their survival. The phosphoinositide 3-kinase delta (PI3Kd) is one of the key proteins participating in the propagation of the BCR signal and integrating signals from chemokine receptors, CD40 protein and integrins. Increased activity of this kinase was particularly observed in lymphoid derived tumors, including CLL. Idelalisib (GS-1101, CAL-101) is currently the only approved and available in clinical practice PI3Kd inhibitor, which showed promising activity in the preclinical studies and clinical trials. In this publication we discuss the mechanism of action, clinical activity and adverse event profile of idelalisib treatment.
Keywords: chronic lymphocytic leukemiaB-cell receptorphosphoinositide 3-kinase delta
References
- Eichhorst B, Robak T, Montserrat E, et al. ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5: v78–v84.
- Hallek M. Prognostic factors in chronic lymphocytic leukemia. Ann Oncol. 2008; 19(supl. 4): iv51–iv53.
- Cramer P, Langerbeins P, Eichhorst B, et al. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). Eur J Haematol. 2016; 96(1): 9–18.
- Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015; 90(5): 446–460.
- Rai KR, Jain P. Chronic lymphocytic leukemia (CLL)-Then and now. Am J Hematol. 2016; 91(3): 330–340.
- Stilgenbauer S, Furman RR, Zent CS. Management of chronic lymphocytic leukemia. Am Soc Clin Oncol Educ Book. 2015: 164–175.
- Brown JR, Porter DL, O'Brien SM. Novel treatments for chronic lymphocytic leukemia and moving forward. Am Soc Clin Oncol Educ Book. 2014: e317–e325.
- Liu TM, Woyach JA, Zhong Y, et al. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012; 120(6): 1175–1184.
- ten Hacken E, Burger JA, Burger JA. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2012; 7(1): 26–33.
- Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012; 13(3): 195–203.
- Okkenhaug K, Burger JA. PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). Curr Top Microbiol Immunol. 2016; 393: 123–142.
- Burger JA, Okkenhaug K. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies. Nat Rev Clin Oncol. 2014; 11(4): 184–186.
- Ramadani F, Bolland DJ, Garcon F, et al. The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signal. 2010; 3(134): ra60.
- Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science. 2002; 297(5583): 1031–1034.
- Jou ST, Carpino N, Takahashi Y, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol. 2002; 22(24): 8580–8591.
- Vanhaesebroeck B, Ali K, Bilancio A, et al. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci. 2005; 30(4): 194–204.
- Vanhaesebroeck B, Khwaja A. PI3Kδ inhibition hits a sensitive spot in B cell malignancies. Cancer Cell. 2014; 25(3): 269–271.
- Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011; 118(13): 3603–3612.
- Fiorcari S, Brown WS, McIntyre BW, et al. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One. 2013; 8(12): e83830.
- Miletic AV, Anzelon-Mills AN, Mills DM, et al. Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J Exp Med. 2010; 207(11): 2407–2420.
- Kang S, Denley A, Vanhaesebroeck B, et al. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A. 2006; 103(5): 1289–1294.
- Meadows SA, Vega F, Kashishian A, et al. PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood. 2012; 119(8): 1897–1900.
- Go H, Jang JY, Kim PJ, et al. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Oncotarget. 2015; 6(17): 15035–15049.
- Psyrri A, Papageorgiou S, Liakata E, et al. Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res. 2009; 15(18): 5724–5732.
- Herman SEM, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010; 116(12): 2078–2088.
- Lannutti BJ, Meadows SA, Herman SEM, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011; 117(2): 591–594.
- Herter S, Palazzo A, Bacac M, et al. The PI3K Delta selective inhibitor idelalisib minimally interferes with immune effector function and B cell depletion mediated by obinutuzumab (GA101) and rituximab. Blood. 2014; 124: 3342–3342.
- Davids MS, Deng J, Wiestner A, et al. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood. 2012; 120(17): 3501–3509.
- Maffei R, Bulgarelli J, Fiorcari S, et al. Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor. PLoS One. 2014; 9(6): e98818.
- Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014; 123(22): 3390–3397.
- Webb HK, Chen H, Yu AS, et al. Clinical pharmacokinetics of CAL-101, a p110d isoform-selective PI3K Inhibitor, following single- and multiple-dose administration in healthy volunteers and patients with hematological malignancies. Blood. 2010; 116: 1774–1774.
- Barrientos JC, Coutre S, De Vos S, et al. Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation. J. Clin. Oncol. . 2015; ; 33 (supl.): abstrakt 7011.
- Nair KS, Cheson B. The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia. Ther Adv Hematol. 2016; 7(2): 69–84.
- De Vos S, Furman RR, Barrientos JC, et al. Idelalisib, a Selective inhibitor of PI3Kd, in combination with bendamustine, fludarabine or chlorambucil in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). Blood. 2013; 122: 2878–2878.
- Barrientos JC, Wagner-Johnston ND, De Vos S, et al. Chemoimmunotherapy combination of idelalisib with bendamustine//rituximab or chlorambucil/rituximab in patients with relapsed/refractory CLL demonstrates efficacy and tolerability. Blood. 2013; 122: 4176–4176.
- Furman RR, de Vo, Barrientos JC, et al. Long-term follow-up of a phase 1 Study of Idelalisib (ZYDELIG ® ) in combination with anti-CD20 antibodies (rituximab [R] or ofatumumab [O]) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood. 2014; 124: 5653–5653.
- Coutre SE, Leonard JP, Furman RR, et al. Combinations of the selective phosphatidylinositol 3-kinase-delta (PI3Kdelta) inhibitor GS-1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): results from a phase I study. Blood. 2012; 120: 191–191.
- Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370(11): 997–1007.
- Jones JA, Wach M, Robak T, et al. Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL). J Clin Oncol. 2015; 33: 7023.
- O'Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015; 126(25): 2686–2694.
- Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016; 128(2): 195–203.
- Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015; 56(10): 2779–2786.
- Brown J. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia. Seminars in Oncology. 2016; 43(2): 260–264.
- Weidner AS, Panarelli NC, Geyer JT, et al. Idelalisib-associated Colitis: Histologic Findings in 14 Patients. Am J Surg Pathol. 2015; 39(12): 1661–1667.
- Louie CY, DiMaio MA, Matsukuma KE, et al. Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides. Am J Surg Pathol. 2015; 39(12): 1653–1660.
- Cheah CY, Fowler NH. Idelalisib in the management of lymphoma. Blood. 2016; 128(3): 331–336.
- Smith SM, Pitcher B, Jung S, et al. H. Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: alliance A051201 and A051202. Blood. 2014; 124: 3091–3091.
- Cheah CY, Nastoupil LJ, Neelapu SS, et al. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015; 125(21): 3357–3359.
- Barr PM, Saylors GB, Spurgeon SE, et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 2016; 127(20): 2411–2415.
- Cheah CY, Fowler NH, Wang ML. Breakthrough therapies in B-cell non-Hodgkin lymphoma. Ann Oncol. 2016; 27(5): 778–787.
- Thompson PA, Stingo F, Keating MJ, et al. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer. 2016; 122(16): 2505–2511.
- Eichhorst B, Robak T, Montserrat E, et al. ESMO Guidelines Committee. appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies). Ann Oncol. 2016; 27(suppl 5): v143–v144.
- Robak T, Hus I, Giannopoulos K, et al. Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2016 r – Raport Grupy Roboczej PTHiT i PALG-CLL. Acta Haematologica Polonica. 2016; 47(3): 169–183.
